CRISPR Therapeutics AG (LON:0VRQ)

CRISPR Therapeutics AG Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-366.25	-153.61	-650.18	377.66	-348.87
Depreciation & Amortization	19.26	19.84	24.17	17.95	9.18
Asset Writedown & Restructuring Costs	-	2.5	-	-	-
Stock-Based Compensation	86.57	81.03	97.95	102.39	66.02
Other Operating Activities	-38.62	-16.55	12.47	14.11	1.86
Change in Accounts Receivable	175	-200	0.31	-0.16	-0.05
Change in Accounts Payable	-27.28	-20.25	5.16	37.51	25.75
Change in Unearned Revenue	-1.95	5.79	-1.01	-0.78	1.38
Change in Other Net Operating Assets	10.5	20.87	15.39	-9.71	6.36
Operating Cash Flow	-142.77	-260.38	-495.74	538.97	-238.37
Capital Expenditures	-1.9	-9.47	-37.19	-81.71	-18.36
Sale (Purchase) of Intangibles	-	-2.5	-	-	-
Investment in Securities	-278.58	386.62	-221.47	-953.73	-522.81
Investing Cash Flow	-280.48	374.65	-258.66	-1,035	-541.17
Issuance of Common Stock	331.98	62.66	38.59	250.95	1,016
Financing Cash Flow	331.98	62.66	38.59	250.95	1,016
Foreign Exchange Rate Adjustments	-0.02	0.07	-0.08	-0.01	0.04
Miscellaneous Cash Flow Adjustments	-	-0	-	-	-
Net Cash Flow	-91.29	177.01	-715.88	-245.52	236.66
Free Cash Flow	-144.68	-269.85	-532.93	457.27	-256.72
Free Cash Flow Margin	-387.72%	-72.69%	-44484.89%	49.98%	-35705.70%
Free Cash Flow Per Share	-1.72	-3.41	-6.86	5.69	-3.89
Levered Free Cash Flow	-29.27	-238.97	-337.58	284.82	-112.91
Unlevered Free Cash Flow	-29.27	-238.97	-337.58	284.82	-112.91
Change in Net Working Capital	-158.41	188.78	1.78	-12.73	-51.77

Updated Feb 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.